TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies
NCT07504263 · Recurv Pharma Inc
RP-001
- Study open to new participants: Matched
Eligibility map · free · live registry data
Every frontier option the patient plausibly meets.
Interventional trials and expanded-access programs, queried live from ClinicalTrials.gov against the profile you enter. Each published criterion comes back as matched, not matched, or honestly unknown — never guessed. Only the trial site can determine actual eligibility.
20 options shownof 1135 open studies found
registry query ↗TRIALNARECRUITING
Evaluate the Safety and Efficacy of BGT007H Cell Therapy in Patients With Relapsed/Refractory Pancreatic Cancer
NCT06478225 · RenJi Hospital
BGT007H Cell Injection
- Study open to new participants: Matched
Nearest sites (1 listed)
- Renji hospital, Shanghai, Shanghai Municipality · RECRUITING
TRIALPHASE1 / PHASE2RECRUITING
Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
NCT05688215 · Jonsson Comprehensive Cancer Center
Biospecimen Collection · Computed Tomography · Core Biopsy · Fluorouracil
- Study open to new participants: Matched
Nearest sites (1 listed)
- Yonemoto,Lisa, Los Angeles, California · RECRUITING
TRIALPHASE1 / PHASE2RECRUITING
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
NCT06819215 · Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
VB15010
- Study open to new participants: Matched
Nearest sites (1 listed)
- Cancer Hospital of Shandong First Medical university, Jinan, Shandong · RECRUITING
TRIALPHASE2RECRUITING
EUS-RFA PANCARDINAL-1 Trial
NCT04990609 · The University of Texas Health Science Center, Houston
Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA) · Neoadjuvant Chemotherapy (NAC)
- Study open to new participants: Matched
Nearest sites (1 listed)
- Memorial Hermann Hospital, Houston, Texas · RECRUITING
TRIALEARLY_PHASE1RECRUITING
A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer
NCT07649928 · Ruijin Hospital
ES502 Injection
- Study open to new participants: Matched
Nearest sites (1 listed)
- Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality · RECRUITING
TRIALPHASE1NOT_YET_RECRUITING
Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer
NCT07488884 · ImmunityBio, Inc.
Nogapendekin Alfa Inbakicept (N803) · Sotevtamab · Zabadinostat (CXD101) · Nab paclitaxel / gemcitabine
- Study open to new participants: Matched
TRIALNARECRUITING
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NCT05837767 · Memorial Sloan Kettering Cancer Center
Palliative radiotherapy
- Study open to new participants: Matched
Nearest sites (7 listed)
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey · RECRUITING
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey · RECRUITING
- Memorial Sloan Kettering Bergen (Limited protocol activities), Montvale, New Jersey · RECRUITING
TRIALNARECRUITING
Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach
NCT05764720 · Varian, a Siemens Healthineers Company
Daily Adaptive External Beam Radiation Therapy
- Study open to new participants: Matched
Nearest sites (3 listed)
- University of Alabama at Birmingham, Birmingham, Alabama · RECRUITING
- Washington University, St. Louis, St Louis, Missouri · RECRUITING
- UH Cleveland Medical Center, Cleveland, Ohio · RECRUITING
TRIALPHASE2RECRUITING
mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients
NCT04084496 · Sun Yat-sen University
Folfirinox
- Study open to new participants: Matched
Nearest sites (1 listed)
- Sun Yat-sen University Cancer Center, Guangzhou, Guangdong · RECRUITING
TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)
NCT07153289 · University Hospital Tuebingen
CD318-CAR-T cells
- Study open to new participants: Matched
TRIALPHASE1 / PHASE2RECRUITING
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
NCT06483555 · UNC Lineberger Comprehensive Cancer Center
Gemcitabine · Nab paclitaxel · Erlotinib · NALIRIFOX
- Study open to new participants: Matched
Nearest sites (1 listed)
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina · RECRUITING
TRIALNANOT_YET_RECRUITING
Surgery and Thermal Hepatic Ablation Combined With Chemotherapy in Hepatic Oligometastatic Pancreatic Cancer
NCT05611359 · Second Affiliated Hospital, Zhejiang University, School of Medicine
Thermal Ablation · Chemotherapy
- Study open to new participants: Matched
TRIALNARECRUITING
MyCap Mobile Application for Tracking Time Burden of Treatment for Patients With Pancreatic Cancer
NCT07619391 · Ohio State University Comprehensive Cancer Center
Electronic Health Record Review · Smartphone Application-based Intervention · Survey Administration
- Study open to new participants: Matched
Nearest sites (1 listed)
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio · RECRUITING
TRIALPHASE3RECRUITING
Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial
NCT05744219 · Jon Unosson
Ferric carboxymaltose · Placebo
- Study open to new participants: Matched
Nearest sites (1 listed)
- Uppsala University Hospital, Uppsala, Sverige · RECRUITING
TRIALPHASE2 / PHASE3RECRUITING
Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer
NCT06601283 · Fudan University
Vitmain C plus herbal medicine
- Study open to new participants: Matched
Nearest sites (1 listed)
- Shanghai Cancer Center, Shanghai · RECRUITING
TRIALPHASE1 / PHASE2RECRUITING
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
NCT07433283 · Sichuan Enray Pharmaceutical Sciences Company
Carbon Nanoparticle-Loaded Iron [CNSI-Fe] · Carbon Nanoparticle-Loaded Iron
- Study open to new participants: Matched
Nearest sites (9 listed)
- Peking Union Medical College Hospital, Beijing, Beijing Municipality · NOT_YET_RECRUITING
- Hunan Provincial Tumor Hospital, Hunan, Changsha · NOT_YET_RECRUITING
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality · RECRUITING
TRIALNARECRUITING
Transdiscal vs Paravertebral Neurolytic Splanchnic Nerve Block for Upper Abdominal Cancer Pain
NCT07445386 · Ankara Etlik City Hospital
transdiscal splanchnic neurolysis · paravertebral splanchnic neurolysis
- Study open to new participants: Matched
Nearest sites (1 listed)
- Ankara Etlik City Hospital, Ankara · RECRUITING
TRIALPHASE2RECRUITING
24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
NCT07043270 · Dartmouth-Hitchcock Medical Center
Nab-paclitaxel + Gemcitabine · modified FOLFIRINOX (mFOLFIRINOX)
- Study open to new participants: Matched
Nearest sites (1 listed)
- Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire · RECRUITING
TRIALPHASE1 / PHASE2RECRUITING
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
NCT07312422 · Zhejiang Provincial People's Hospital
Low-dose Radiotherapy · Pucotenlimab · AG regimen · FOLFIRINOX regimen
- Study open to new participants: Matched
Nearest sites (1 listed)
- Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang · RECRUITING
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors. Results come from Trial0’s live query of ClinicalTrials.gov and reflect what the registry publishes right now.